Edgewise Therapeutics (EWTX) Current Leases (2022 - 2026)
Edgewise Therapeutics (EWTX) posted Current Leases of $1.0 million for Q1 2026, little changed sequentially from $1.0 million in Q4 2025, and up 1.6% YoY from $1.0 million in Q1 2025.
Edgewise Therapeutics (EWTX) Current Leases (2022 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Current Leases for 5 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Current Leases rose 1.6% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 1.6% YoY) and the FY2025 annual result came in at $1.0 million, up 1.81% from the prior year.
- Current Leases was little changed at $1.0 million in Q1 2026 per EWTX's latest filing, from $1.0 million in the prior quarter.
- Over five years, Current Leases peaked at $1.0 million in Q1 2026 and troughed at $104000.0 in Q2 2022.
- A 5-year average of $844062.5 and a median of $986000.0 in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2026: Current Leases surged 738.46% in 2023, then gained 1.6% in 2026.
- Over 5 years, Current Leases stood at $608000.0 in 2022, then surged by 61.18% to $980000.0 in 2023, then increased by 1.63% to $996000.0 in 2024, then grew by 1.81% to $1.0 million in 2025, then gained by 0.3% to $1.0 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.0 million, $1.0 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 1.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.02 Mn |
| Mar 31, 2026 | 1.02 Mn |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.00 Mn |
| Mar 31, 2025 | 1.00 Mn |
| Dec 31, 2024 | 996,000.00 |
| Sep 30, 2024 | 992,000.00 |
| Jun 30, 2024 | 988,000.00 |
| Mar 31, 2024 | 984,000.00 |
| Dec 31, 2023 | 980,000.00 |
| Sep 30, 2023 | 931,000.00 |
| Jun 30, 2023 | 872,000.00 |
| Mar 31, 2023 | 797,000.00 |
| Dec 31, 2022 | 608,000.00 |
| Sep 30, 2022 | 209,000.00 |
| Jun 30, 2022 | 104,000.00 |